Anti-thrombotic strategies with long-term anticoagulation after percutaneous coronary intervention – a systematic review and meta-analysis

Waqas Javed Siddiqui, Mohammad Yasin Khan, Muhammad Shabbir Rawala, Kadambari Jethwani, Mohammad Harisullah Khan, Chikezie Alvarez, Ramsha Kashi, Syed Farhan Hasni, Sandeep Aggarwal, Andrew Kohut and Howard Eisen

*Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA; 1Department of Medicine, Capital Health Regional Medical Center, Trenton, NJ, USA; 2Rapides Regional Medical Center, Alexandria, LA, USA; 3Department of Medicine, Seton Hall University, St. Francis Medical Center, Trenton, NJ, USA; 4Pennsylvania Hospital, University of Pennsylvania, PhiladelpShia, PA, USA; 5Penn State Hershey Heart and Vascular Institute, Hershey, PA, USA

**ABSTRACT**

**Background:** Long-term oral anticoagulants (OAC) increases bleeding risk after the percutaneous coronary intervention (PCI) with dual antiplatelet therapy (DAPT) with Aspirin and P2Y12 inhibitors. We hypothesize that dual anti-thrombotic therapy (DATT) reduces bleeding without increased cardiovascular events.

**Objectives:** DATT does not increase adverse cardiovascular events compared to triple anti-thrombotic therapy (TATT).

**Method:** We searched MEDLINE, PUBMED, Google Scholar, Cochrane and EMBASE from inception to 6 April 2019 for randomized control trials (RCTs) comparing DATT to TATT after PCI.

**Results:** We identified 641 citations (411 after excluding duplicates). Four RCTs with 5,317 patients (3,039 on DATT vs 2,278 on TATT) were included. DATT arm showed significantly reduced [total bleeding, 731 vs 784; odds ratio (OR) = 0.51, Confidence Interval (CI) = 0.39–0.67, p < 0.00001, I^2 = 71% (I^2 = 0% without WOEST study)], [TIIMI major bleeding 60 vs 80, OR = 0.56, CI = 0.4–0.79, p = 0.0009, I^2 = 0%], and [TIIMI minor bleeding, 70 vs 126, OR = 0.43, CI = 0.32–0.59, p < 0.00001, I^2 = 0%]. There was no difference in subsequent strokes, myocardial infarction, stent thrombosis, and mortality. A trend towards decreased non-cardiac deaths with DATT was observed, 14 vs 26, OR = 0.55, CI = 0.27–1.10, p = 0.09, I^2 = 6%.

**Conclusions:** DATT is associated with significantly reduced bleeding and a trend towards reduced non-cardiac death with no difference in adverse cardiovascular outcomes.

1. Introduction

Dual antiplatelet therapy (DAPT) using Aspirin and P2Y12 inhibitors is the standard of care after the percutaneous coronary intervention (PCI) and stent placement. It is superior in the prevention of stent thrombosis post PCI as compared to oral anticoagulant (OAC) alone [1,2]. On the other hand, OAC is preferred in reducing the risk of thromboembolic events as compared to DAPT in patients with mechanical heart valves [3], and atrial fibrillation [4]. Patients undergoing PCI with a concomitant indication for long-term anticoagulation are treated with triple antithrombotic therapy (TATT). This strategy consists of the combined use of DAPT and OAC [5–7]. One-fourth of elderly patients with atrial fibrillation and myocardial infarction also requires TATT [8]. However, this strategy is associated with an increase in bleeding complications with rates of 2.2% within the first month and increasing to 4% to 12% within the first year of treatment and more than three folds compared to Warfarin alone [9,10]. Patients receiving TATT are also more likely to be admitted to the hospital [11].

These findings have led to studies considering new therapeutic approaches to reduce the risk of bleeding in patients on both OAC and DAPT. There is an increasing interest in utilizing non-vitamin K antagonist OAC as studies have shown novel oral anticoagulants may provide an advantage over vitamin K antagonist (VKA) [12]. Dewilde et al. in their randomized controlled trial (RCT) showed that dual therapy with Clopidogrel and Warfarin might be considered as an alternative to initial triple treatment in selected patients [13]. Other studies have demonstrated the use of low dose Rivaroxaban along with P2Y12 inhibitor was associated with reduced bleeding rates compared to triple therapy [14–16].

We have conducted a comprehensive systemic review and meta-analysis combining all previous RCTs...
comparing triple antithrombotic therapy (TATT) (dual antiplatelet therapy plus oral anticoagulant with either warfarin or non-vitamin K antagonist) vs. dual antithrombotic therapy (DATT) (an antiplatelet agent plus an oral anticoagulant with either warfarin or non-vitamin K antagonist). We performed this analysis to elucidate the clinical outcomes, and adverse events associated with the DATT in patients who are undergoing PCI and simultaneously require long-term OAC.

2. Methods

2.1. Study selection protocol

We included only those studies for final analysis which met our predefined inclusion criteria.

Inclusion Criteria – 1) Prospective RCT’s, 2) Comparing only DATT to TATT in patients undergoing PCI and also require long-term anti-thrombotic therapy, 3) Adult patients (age ≥ 18 years), 4) All of the following outcomes were addressed: I – Any bleeding (including major and minor), II – thromboembolic events (including ischemic stroke, stent thrombosis or MI), and III – death (cardiac and non-cardiac).

2.2. Information sources and search strategy

We completed our systematic review per the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines [17]. A comprehensive review of PubMed, MEDLINE, Google Scholar, Cochrane and EMBASE databases was completed from inception until 6 April 2019, for the studies comparing DATT to TATT after PCI in patients who require long-term anticoagulation. We used the MeSH terms and keywords for our search. We used following search strategy (‘percutaneous coronary intervention’ OR PCI) AND (antiplatelet OR aspirin OR clopidogrel OR prasugrel OR ticagrelor) AND (NOAC OR DOAC OR anticoagulation OR anticoagulant OR antithrombotic OR warfarin OR dabigatran OR apixaban OR rivaroxaban OR edoxaban). We combined search themes using the Boolean operator ‘AND’ and ‘OR.’ Our initial search was not limited by language or publication year, but it was limited to RCTs.

2.3. Study selection

The initial search yielded a total of 649 articles, after excluding the duplicates, they reduced to 411. We excluded 394 studies based on titles and abstracts which included cohort studies, non-randomized trials, post hoc analysis of original trials, review articles, editorials, and retrospective studies. We read full texts of 17 studies, of which 13 were excluded. Only four studies met our inclusion criteria which we included in our analysis [13,15,18,19]. Out of 13 excluded studies, five studies were the sub-studies of original RCTs; eight were the trial designs. We searched the clinical trials.gov for the study designs of three trials whose completed trials did not appear in our search and were published before 2017 [20–22]. When we contacted the corresponding authors, we did not receive any response from them. One study’s design was published in 2017, and this study is currently underway [23]. The included trials compared DATT to TATT post PCI in patients requiring long-term anticoagulation. We then searched through the references of individual papers, but we did not come across any additional RCTs meeting our inclusion criteria.

2.4. Data collection process

Three independent reviewers (W.J.S, M.S.R., and M.Y.K.) selected the studies. Two reviewers (W.J.S. and C.A.) extracted the data using the pre-defined data fields. W.J.S. cross-checked all the entered data. We resolved any discrepancies within the data entry after mutual discussion and understanding. Figure 1 shows the study flow diagram.

2.5. Risk of bias in individual studies

We assessed the quality of the individual study using the Cochrane collaboration’s tool for determining the risk of bias in randomized trials [24]. These are summarized in Table 1 and Supplementary Figure 1.

2.6. Data synthesis and analysis

The PIONEER AF-PCI trial used two different doses of Rivaroxaban (10/15mg vs. 2.5 mg) in the TATT arm. We only used outcomes from the group which used a higher dose (10/15mg) for our analysis. Also, to mention that ISAR-TRIPLE trial used Warfarin, Clopidogrel, and Aspirin in the trial. It was primarily designed to evaluate short duration (six weeks) vs. long duration (six months) of TATT where Clopidogrel was used only for the first six weeks in the short duration arm and after that aspirin was continued with warfarin. We only assessed events after the initial six-week period between 6 weeks and nine months when the real comparison of DATT vs. TATT was made. The censored events from the first six weeks of the trial and the events used in our analysis between the six weeks and six months are summarized in supplementary appendix Table 1. The two older trials, the WOEST trial, and the ISAR-TRIPLE trial used Warfarin for the anticoagulation [13,19] as compared to the two newer trials, the PIONEER AF-PCI and the RE-DUAL PCI trial which used Rivaroxaban and Dabigatran, respectively, [15,18]. We assessed the following endpoints.
The primary endpoints were 1) all-cause bleeding, 2) Thrombolysis in Myocardial Infarction (TIMI) major bleeding and 3) TIMI minor bleeding.

The secondary endpoints were 1) all strokes, 2) ischemic strokes, 3) hemorrhagic strokes, 4) myocardial infarction, 5) stent thrombosis, 6) all-cause death, 7) cardiovascular cause of death and 8) non-cardiac death.

2.7. Statistical method

We used the random effects model for our statistical analysis in RevMan Version 5.3 Copenhagen. We used the Mantel-Haenszel method for the statistical analysis of dichotomous data to calculate the odds ratio. We used the effect estimate to report our results. 95% confidence interval, with 2-sided p-value of <0.05 was considered statistically significant. Baseline characteristics and differences of individual studies are summarized in Supplementary Table 2 and Table 2, respectively.

2.8. Heterogeneity

We used Chi² and I² statistics for calculating the heterogeneity with RevMan Version 5.3 Copenhagen. We estimated the percentage of variability present between studies (inter-study variability) compared to the variability present in individual studies (intra-study) with the I² statistic. An I² value of >50% was classified as the substantial existence of heterogeneity as explained by the Cochrane Handbook for Systematic Reviews for Interventions, Version 5.1.0, Part 2: General Methods for Cochrane Reviews [25]. We performed a sensitivity analysis on outcomes where substantial heterogeneity was present.

3. Results

We found 649 articles, which were reduced to 411 after removing duplicated. After screening based on title and abstract, we excluded 394 studies which included cohort studies, non-randomized studies,
post hoc analysis of original trials, review articles, editorials, and retrospective studies. We read full texts of 17 studies, of which 13 were excluded. Five were sub-studies of the original trials included in the analysis and eight were the study designs. Only four studies met our inclusion criteria which we included in our analysis [13,15,18,19]. We searched the clinicaltrials.gov for the study designs of three trials whose completed trials did not appear in our search and were published before 2017 [20–22]. We included four RCT’s with 5,317 patients for our analysis. There were a total of 3,039 patients in DATT group compared to 2,278 in TATT arm.

### 3.1. Primary outcomes

There was significantly decreased number of bleeding episodes in DATT group compared to TATT group, 731 vs 786 (odds ratio [OR] = 0.51, Confidence Interval [CI] = 0.39–0.67, p < 0.00001, I² = 71%), (Figure 2a). Since I² was 71% which suggested substantial heterogeneity, on running the sensitivity analysis without WOEST study, (9) I² decreased to 0% with results still significantly favoring DATT over TATT. On assessing the TIIMI major bleeding, there were a total of 60 episodes in DATT group which was significantly lower compared to 80 in TATT group, (OR = 0.56, CI = 0.4–0.79, p = 0.0009, I² = 0%), (Figure 2b). Similarly, on assessing the On TIIMI minor bleeding, there were significantly decreased episodes in the DATT vs TATT group, (70 vs 126, OR = 0.43, CI = 0.32–0.59, p < 0.00001, I² = 0%) (Figure 2c).

### 3.2. Secondary outcomes

There was no significant difference in all strokes (43 vs 40 in DATT vs TATT, OR = 0.75, CI = 0.48–1.17, p = 0.20, I² = 0%), ischemic strokes (36 vs 26 in DATT vs TATT, OR = 0.91, CI = 0.39–2.14, p = 0.83, I² = 41%) and hemorrhagic strokes (7 vs 13 in DATT vs TATT, OR = 0.49, CI = 0.14–1.73, p = 0.27, I² = 27%) Supplementary Figure 2. There was also no difference in the cardiac events including MI with 99 vs 63 in DATT and TATT arms, respectively, (OR = 1.12, CI = 0.80–1.55, p = 0.52, I² = 0%). Number of in-stent thrombosis was also similar in both groups 31 vs 21 in DATT and TATT arms, respectively (OR = 1.03, CI = 0.48–2.19, p = 0.94, I² = 32%) Supplementary Figure 3. On assessing the mortality, there was no statistical difference in all cause death, (120 in DATT and 100 in TATT arms, OR = 0.80, CI = 0.55–1.16, p = 0.24, I² = 29%). CV cause of death was also similar in both groups, (21 in DATT vs 26 in TATT, OR = 0.70, CI = 0.28–1.74, p = 0.44, I² = 49%). There was a trend towards decreased non-cardiac deaths in DATT patients compared to TATT arm (14 vs 26, OR = 0.55, CI = 0.27–1.10, p = 0.09, I² = 6%), Supplementary Figure 4.
### Table 2. Characteristics and differences of RCT’s.

| Name | RE – DUAL PCI | PIONEER AF-PCI | ISAR-TRIPLE | WOEST Dewilde et al |
|------|---------------|----------------|-------------|---------------------|
| Design | Prospective, Multicenter, Open Label Blinded end point RCT | Prospective, Multicenter, Open Label Blinded end point RCT | Prospective, Multicenter, Open Label, RCT | Prospective, Multicenter, Open-label, RCT |
| Country | USA, Europe, Japan, other countries (41 countries) | Multiple Countries | Germany, Denmark | Netherlands and Belgium (15 sites) |
| Publication Year Journal Enrolment | 2017 NEJM July 2014 – October 2016 | 2016 NEJM Unknown | 2015 JACC September 2008 – December 2013 | 2013 Lancet November 2008 – November 2011 |
| Population Indication of Anticoagulation | NVAF patients > 18 years old s/p successful PCI with BMS or DES | Atrial Fibrillation (100%) | Patients receiving OAC for ≥ 12 months + receiving DES for Stable Angina or ACS | Atrial Fibrillation (84%), Mechanical Valve (7%), Other (9%) |
| Intervention vs Comparison | Dabigatran + SAPT vs Warfarin + DAPT | LD Rivaroxaban + P2Y12 Inhibitors vs VLD Rivaroxaban + DAPT vs Warfarin + DAPT | Aspirin + Warfarin + 6-week of Clopidogrel vs Aspirin + Warfarin + 6-month of Clopidogrel | Warfarin + Clopidogrel (Double Therapy) vs Warfarin + Clopidogrel + Aspirin (Triple Therapy) |
| Primary Outcome F/u Duration | Major or clinically relevant nonmajor bleeding event during follow-up | Composite of major bleeding or minor bleeding according to TIMI criteria or bleeding requiring medical attention | Composite of death, MI, definite stent thrombosis, stroke, or TIMI major bleeding at 9 months | Any bleeding episode within 1 year of Percutaneous Intervention |
| | 14 months | 12 months | 9 months | 12 months |

**RCT** = Randomized Control Trial, **NEJM** = New England Journal of Medicine, **JACC** = Journal of American College of Cardiology, **NVAF** = Non-Valvular Atrial Fibrillation, **OAC** = Oral Anti-Coagulation, **DES** = Drug Eluting Stent, **ACS** = Acute Coronary Syndrome, **SAPT** = Single Anti-Platelet Therapy (Clopidogrel or Ticagrelor), **DAPT** = Dual Anti-Platelet Therapy (Clopidogrel or Ticagrelor + Aspirin), **LD** = Low Dose, **VLD** = Very Low Dose, **TIMI** = Thrombolysis in Myocardial Infarction, **MI** = Myocardial Infarction.

### 4. Discussion

The patients undergoing PCI who require long-term OAC most commonly secondary to atrial fibrillation, the choice, and duration of therapy presents a significant challenge to clinicians. It is a balance between the risk of stroke/emboli (CHA2DS2-VASc score), recurrent ischemic events, stent thrombosis, and major bleeding [5]. Most commonly used combinations are: i) triple antithrombotic therapy (TATT) with a DAPT (aspirin and P2Y12 inhibitor) plus an oral VKA or a non-vitamin K oral anticoagulant (NOAC), or ii) oral anticoagulation plus aspirin or a P2Y12 inhibitor [5]. As treatment with TATT confers almost a 2–3 fold increased risk in bleeding complications, recent guidelines have recommended that the duration of triple therapy should be as short as possible, followed by OAC plus a single antiplatelet therapy [7,26,27]. DATT with an OAC (either with NOAC or a VKA) and Clopidogrel 75 mg/day may be considered an alternative to initial triple therapy in selected patients with CHA2DS2–VASc score ≥2 [7,26,28]. To date, there has been no systematic review and meta-analysis of only RCTs comparing DATT to TATT.

In our analysis, there was a significantly decreased incidence of all-cause bleeding, TIMI major bleeding and TIMI minor bleeding in the DATT group as compared to the TATT group. These results are consistent with the results of individual RCTs and endorse that DAPT is safe as compared to TATT in patients who need long-term anticoagulation and also require concomitant antiplatelet therapy [19]. One cohort study found that the risk of bleeding with TATT was greatest within 30 days post-PCI [29]. Several studies have suggested that bleeding after PCI is an independent risk factor for mortality. This risk is even higher in patients who need red blood cell transfusion [30–32]. The current antithrombotic recommendation in high-risk patients for bleeding with atrial fibrillation undergoing PCI is to use single antiplatelet therapy (SAPT) with either VKA or NOAC (preferably NOAC) post stent placement. This recommendation further suggests discontinuing SAPT after one year if the patient remains at low risk for the thrombotic event. Patients with a high risk of thrombotic events should be given DAPT for at least 3–6 months after stent placement. The duration of DAPT depends on the type of stent used, with three months for a bare-metal stent and six months for drug-eluting stents. Subsequently, SAPT should be continued for life unless the patient is at low risk of thrombotic events when SAPT can be discontinued after 12 months [33,34]. Before initiating either TATT or DATT, bleeding and thromboembolic
risks should be ascertained using the CHA2DS2-VASc and the HAS-BLED scores to individualize the treatment strategy.

Our meta-analysis did not reveal any significant difference in the cardiovascular events of strokes, MI and stent thrombosis between the two treatment arms of DATT and TATT. There was also no difference in the all-cause and cardiovascular cause of mortality. However, there was a trend towards decreased non-cardiac deaths in the DATT group compared to the TATT group. This reduced trend in non-cardiac deaths in the DATT group can likely be reflected by the significant decrease in bleeding events in the DATT group compared to the TATT group. Our findings differ from a previous meta-analysis by Briasoulis et al., which found a significant decrease in MI's in the TATT group compared to the DATT group. These results could have been affected by population selection bias which included five cohort studies. Our meta-analysis has several limitations and should be carefully considered before inferring any additional conclusions. The first limitation is that two studies used warfarin and the other two studies used NOACs which creates a heterogeneity between the treatments arms since Warfarin is known to cause a higher incidence of bleeding episodes compared to the NOACs. Rivaroxaban has also been associated with a lower risk of stroke, and systemic embolism than VKA and it also associated with significantly lower rates of intracranial hemorrhage and fatal bleeding. Therefore, it is possible that TATT with Rivaroxaban would has equally reduced adverse events without excess bleeding if it was compared to DATT with Rivaroxaban. The second limitation is that the treatments were un-blinded which could potentially lead to a bias. The third limitation was the indication for long-term OAC which was not uniform across the studies with two studies were purely done on patients with pre-existing atrial fibrillation, and other two studies had other indications of long-term OAC. The fourth limitation is the administration of TATT to both arms in the ISAR-TRIPLE trial for the initial six weeks which is the most sensitive time for adverse events. The last limitation was the lack of availability of the patient level data which does not allow the more critical analysis of different risk groups where longer and shorter duration of TATT may be of an advantage.

5. Conclusion

The results of our analysis show a significant decrease in the incidence of bleeding in patients who receive DATT over TATT without any significant rise in thromboembolic events or CV death. In the future, trials comparing different DATT with head-to-head comparison of oral anticoagulants to each other and standard of care with Warfarin are required with an extended follow-up time on a large and diverse population to elucidate the difference that exists between different oral anticoagulants.
Disclosure statement

No potential conflict of interest was reported by the authors.

Funding

No funding was received for any aspect of this study.

ORCID

Waqas Javed Siddiqui  http://orcid.org/0000-0001-9314-211X
Chikeye Alvarez  http://orcid.org/0000-0003-2664-6371

References

[1] Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, et al. Guidelines on myocardial revascularization. Eur Heart J. 2010 Oct;31(20):2501–2553. PubMed PMID: 20802248.

[2] Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996 Apr 25;334(17):1084–1089. PubMed PMID: 8598866.

[3] Schlitt A, von Bardeleben RS, Ehrlich A, et al. Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thromb Res. 2003 Jan 25;109 (2–3):131–135. PubMed PMID: 12706642; eng.

[4] Investigators AWGotA, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulant therapy for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006 Jun 10;367 (9862):1903–1912. PubMed PMID: 16765759.

[5] Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost. 2011 Oct;106(4):572–584. PubMed PMID: 21785642; eng.

[6] European Heart Rhythm A, European Association for Cardio-Thoracic S, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369–2429. PubMed PMID: 20802247.

[7] Lip GY, Windecker S, Huber K, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014 Dec 01;35(45):3155–3179. PubMed PMID: 25154388.

[8] Hess CN, Peterson ED, Peng SA, et al. Use and outcomes of triple therapy among older patients with acute myocardial infarction and atrial fibrillation. J Am Coll Cardiol. 2015 Aug 11;66(6):616–627. PubMed PMID: 26248987; eng.

[9] Paikin JS, Wright DS, Crowther MA, et al. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010 May 11;121(18):2067–2070. PubMed PMID: 20458022.

[10] Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Internal Med. 2010 Sep 13;170 (16):1433–1441. PubMed PMID: 20837828; eng.

[11] Lopes RD, Rao M, Simon DN, et al. Triple vs dual antithrombotic therapy in patients with atrial fibrillation and coronary artery disease. Am J Med. 2016 Jun;129(6):592–599.e1. PubMed PMID: 26797080; eng.

[12] Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–891. PubMed PMID: 21809575; eng.

[13] Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013 Mar 30;381 (9872):1107–1115. PubMed PMID: 23415013; eng.

[14] Bhatt DL. O PIONEERS! The beginning of the end of full-dose triple therapy with warfarin? Circulation. 2017 Jan 24;135(4):334–337. PubMed PMID: 27881554; eng.

[15] Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016 Dec 22;375(25):2423–2434. PubMed PMID: 27959713; eng.

[16] Gibson CM, Pinto DS, Chi G, et al. Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy. Circulation. 2017 Jan 24;135(4):323–333. PubMed PMID: 27881555; PubMed Central PMCID: PMCPMC5266420; eng.

[17] Liberati A, Di G A, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009 Jul;21(339):b2700. PubMed PMID: 19622552; PubMed Central PMCID: PMCPMC2714672; eng.

[18] Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017 Oct 19;377 (16):1513–1524. PubMed PMID: 28844193; eng.

[19] Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015 Apr 28;65(16):1619–1629. PubMed PMID: 25908066; eng.

[20] Sambola A, Montoro JB, Del Blanco BG, et al. Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: design of the MUSICA-2 randomized trial. Am Heart J. 2013 Oct;166(4):669–675. PubMed PMID: 24093846; eng.
[21] Lu W, Chen L, Wang Y, et al. Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS. Contemp Clin Trials. 2015 Jan;40:166–171. PubMed PMID: 25513965; eng.

[22] Gao F, Shen H, Wang ZJ, et al. Rationale and design of the RT-AF study: combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention. Contemp Clin Trials. 2015 Jul;43:129–132. PubMed PMID: 26003433; eng.

[23] Hoshi T, Sato A, Nogami A, et al. Rationale and design of the SAFE-A study: sAFety and Effectiveness trial of Apixaban use in association with dual antplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. J Cardiol. 2017 Apr;69(4):648–651. PubMed PMID: 27443596.

[24] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ (Clin Res Ed). 2011 Oct;18(343):d5928. PubMed PMID: 22008217; PubMed Central PMCID: PMCPMC3196245. eng. .

[25] Higgins JPT GD. Cochrane handbook of systematic reviews of interventions 5.1.0 part 2: general methods for cochrane reviews. Cochrane Collab. 2011. Available at: http://handbook.cochrane.org/chapter_9/9_5_2_identifying_and_measuring_heterogeneity.htm.

[26] January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130 (23):2071–2104. PubMed PMID: 24682348.

[27] Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCC/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016 Sep 06;134(10):e123–55. PubMed PMID: 27026020; eng.

[28] Steg PG, Bhatt DL. Viewpoint: a proposal for a simple algorithm for managing oral anticoagulation and antiplatelet therapy in patients with non-valvular atrial fibrillation and coronary stents. Eur Heart J Acute Cardiovasc Care. 2017 Feb;6(1):93–97. PubMed PMID: 26463061.

[29] Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012 Sep 04;126(10):1185–1193. PubMed PMID: 22869839.

[30] Doyle BJ, Rihal CS, Gastineau DA, et al. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009 Jun 02;53(22):2019–2027. PubMed PMID: 19477350.

[31] Kim P, Dixon S, Eisenbrey AB, et al. Impact of acute blood loss anemia and red blood cell transfusion on mortality after percutaneous coronary intervention. Clin Cardiol. 2007 Oct;30(10 Suppl 2):II35–43. PubMed PMID: 18228650.

[32] Ndrepepa G, Berger PB, Mehilli J, et al. Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol. 2008 Feb 19;51(7):690–697. PubMed PMID: 18279731.

[33] Angiolillo DJ, Goodman SG, Bhatt DL, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a north american perspective-2016 update. Circ Cardiovasc Interventions. 2016 Nov;9(11). PubMed PMID: 27803042; eng. DOI:10.1161/circinterventions.116.004395.

[34] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893–2962. PubMed PMID: 27567408; eng.

[35] Briasoulis A, Papageorgiou N, Zacharia E, et al. Meta-analysis of oral anticoagulants with dual versus single antplatelet therapy in patients after percutaneous coronary intervention. Am J Cardiovasc Drugs. 2016 Apr;16(2):103–110. PubMed PMID: 26650924.